Novartis | NVS - Cost Of Sales

Stock Price
169.24
Daily Change
2.13 1.27%
Monthly
14.44%
Yearly
55.22%
Q1 Forecast
161.20

Novartis reported $3.54B in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bausch Health Companies USD 1.03B 284M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Canopy Growth CAD 44.78M 9.32M Sep/2025
Corcept Therapeutics USD 2.54M 2.05M Dec/2025
Drreddys Laboratories INR 40.46B 3.64B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Glaxosmithkline GBP 3.01B 853.01M Sep/2025
J&J USD 7.97B 689M Dec/2025
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 217M Sep/2025
Novartis USD 3.54B 216M Sep/2025
Pacira USD 54.62M 6.02M Dec/2025
Perrigo USD 747.4M 81.2M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Phibro Animal Health USD 207.39M 30.45M Dec/2024
Prestige Brands USD 131.22M 3.52M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Sanofi EUR 3.76B 344M Dec/2025
Supernus Pharmaceuticals USD 47.53M 4.24M Dec/2025
Zoetis USD 743M 60M Dec/2025